Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Choosing the best trastuzumab-based adjuvant chemotherapy regimen: should we abandon anthracyclines?

Literature DB >> 22614986

Choosing the best trastuzumab-based adjuvant chemotherapy regimen: should we abandon anthracyclines?

Harold J Burstein¹, Martine J Piccart-Gebhart, Edith A Perez, Gabriel N Hortobagyi, Norman Wolmark, Kathy S Albain, Larry Norton, Eric P Winer, Clifford A Hudis.

Abstract

Entities: Chemical

Mesh：

Substances：

Year: 2012 PMID： 22614986 PMCID： PMC6076002 DOI： 10.1200/JCO.2012.42.0695

Source DB: PubMed Journal: J Clin Oncol ISSN： 0732-183X Impact factor: 44.544

× No keyword cloud information.

18 in total

1. Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer.

Authors: Soley Bayraktar; Ana M Gonzalez-Angulo; Xiudong Lei; Aman U Buzdar; Vicente Valero; Amal Melhem-Bertrandt; Henry M Kuerer; Gabriel N Hortobagyi; Aysegul A Sahin; Funda Meric-Bernstam
Journal: Cancer Date: 2011-09-27 Impact factor: 6.860

2. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.

Authors: Edith A Perez; Edward H Romond; Vera J Suman; Jong-Hyeon Jeong; Nancy E Davidson; Charles E Geyer; Silvana Martino; Eleftherios P Mamounas; Peter A Kaufman; Norman Wolmark
Journal: J Clin Oncol Date: 2011-07-18 Impact factor: 44.544

3. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.

Authors: Luca Gianni; Wolfgang Eiermann; Vladimir Semiglazov; Alexey Manikhas; Ana Lluch; Sergey Tjulandin; Milvia Zambetti; Federico Vazquez; Mikhail Byakhow; Mikhail Lichinitser; Miguel Angel Climent; Eva Ciruelos; Belén Ojeda; Mauro Mansutti; Alla Bozhok; Roberta Baronio; Andrea Feyereislova; Claire Barton; Pinuccia Valagussa; Jose Baselga
Journal: Lancet Date: 2010-01-30 Impact factor: 79.321

4. Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer.

Authors: Edith A Perez; Vera J Suman; Nancy E Davidson; Julie R Gralow; Peter A Kaufman; Daniel W Visscher; Beiyun Chen; James N Ingle; Shaker R Dakhil; Joanne Zujewski; Alvaro Moreno-Aspitia; Thomas M Pisansky; Robert B Jenkins
Journal: J Clin Oncol Date: 2011-10-31 Impact factor: 44.544

5. Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinib.

Authors: Patrick G Morris; Carol Chen; Richard Steingart; Martin Fleisher; Nancy Lin; Beverly Moy; Steven Come; Steven Sugarman; Alyson Abbruzzi; Robert Lehman; Sujata Patil; Maura Dickler; Heather L McArthur; Eric Winer; Larry Norton; Clifford A Hudis; Chau T Dang
Journal: Clin Cancer Res Date: 2011-03-03 Impact factor: 12.531

6. Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens.

Authors: Vicente Valero; John Forbes; Mark D Pegram; Tadeusz Pienkowski; Wolfgang Eiermann; Gunter von Minckwitz; Henri Roche; Miguel Martin; John Crown; John R Mackey; Pierre Fumoleau; Janusz Rolski; Zrinka Mrsic-Krmpotic; Agnieszka Jagiello-Gruszfeld; Alessandro Riva; Marc Buyse; Henry Taupin; Guido Sauter; Michael F Press; Dennis J Slamon
Journal: J Clin Oncol Date: 2010-11-29 Impact factor: 44.544

7. Adjuvant trastuzumab in HER2-positive breast cancer.

Authors: Dennis Slamon; Wolfgang Eiermann; Nicholas Robert; Tadeusz Pienkowski; Miguel Martin; Michael Press; John Mackey; John Glaspy; Arlene Chan; Marek Pawlicki; Tamas Pinter; Vicente Valero; Mei-Ching Liu; Guido Sauter; Gunter von Minckwitz; Frances Visco; Valerie Bee; Marc Buyse; Belguendouz Bendahmane; Isabelle Tabah-Fisch; Mary-Ann Lindsay; Alessandro Riva; John Crown
Journal: N Engl J Med Date: 2011-10-06 Impact factor: 91.245

8. HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials.

Authors: Alessandra Gennari; Maria Pia Sormani; Paolo Pronzato; Matteo Puntoni; Mariantonietta Colozza; Ulrich Pfeffer; Paolo Bruzzi
Journal: J Natl Cancer Inst Date: 2007-12-25 Impact factor: 13.506

Review 9. Role of anthracyclines in the treatment of early breast cancer.

Authors: Luca Gianni; Larry Norton; Norman Wolmark; Thomas M Suter; Gianni Bonadonna; Gabriel N Hortobagyi
Journal: J Clin Oncol Date: 2009-08-17 Impact factor: 44.544

10. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer.

Authors: Mark D Pegram; Gottfried E Konecny; Carminda O'Callaghan; Malgorzata Beryt; Richard Pietras; Dennis J Slamon
Journal: J Natl Cancer Inst Date: 2004-05-19 Impact factor: 13.506

13 in total

1. Cardiac safety of non-anthracycline trastuzumab-based therapy for HER2-positive breast cancer.

Authors: Anthony F Yu; Roy B Mukku; Shivani Verma; Jennifer E Liu; Kevin C Oeffinger; Richard M Steingart; Clifford A Hudis; Chau T Dang
Journal: Breast Cancer Res Treat Date: 2017-07-14 Impact factor: 4.872

2. Correlation between financial relationships with commercial interests and research prominence at an oncology meeting.

Authors: Beverly Moy; Angela R Bradbury; Paul R Helft; Brian L Egleston; Moktar Sheikh-Salah; Jeffrey Peppercorn
Journal: J Clin Oncol Date: 2013-06-17 Impact factor: 44.544

Review 3. The trastuzumab era: current and upcoming targeted HER2+ breast cancer therapies.

Authors: Jordyn Kreutzfeldt; Brett Rozeboom; Nandini Dey; Pradip De
Journal: Am J Cancer Res Date: 2020-04-01 Impact factor: 6.166

4. Cardiac Safety of Dual Anti-HER2 Therapy in the Neoadjuvant Setting for Treatment of HER2-Positive Breast Cancer.

Authors: Anthony F Yu; Jasmeet C Singh; Rui Wang; Jennifer E Liu; Anne Eaton; Kevin C Oeffinger; Richard M Steingart; Clifford A Hudis; Chau T Dang
Journal: Oncologist Date: 2017-03-24

5. DNA repair gene patterns as prognostic and predictive factors in molecular breast cancer subtypes.

Authors: Libero Santarpia; Takayuki Iwamoto; Angelo Di Leo; Naoki Hayashi; Giulia Bottai; Martha Stampfer; Fabrice André; Nicholas C Turner; W Fraser Symmans; Gabriel N Hortobágyi; Lajos Pusztai; Giampaolo Bianchini
Journal: Oncologist Date: 2013-09-26

6. Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Results of a Prospective, Noninterventional Study on Routine Treatment Between 2006 and 2012 in Germany.

Authors: Peter Dall; Thorsten Koch; Thomas Göhler; Johannes Selbach; Andreas Ammon; Jochen Eggert; Nidal Gazawi; Daniela Rezek; Arthur Wischnik; Carsten Hielscher; Stella Keitel; Ursula Cirrincione; Axel Hinke; Gabriele Feisel-Schwickardi
Journal: Oncologist Date: 2017-02-07